Results 121 to 130 of about 6,007,439 (376)

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Frontiers in Pharmacology
IntroductionAnxiety diagnoses have surged recently during and after the COVID-19 pandemic. Lorazepam is widely recognized for its efficacy in treatment of anxiety, as well as insomnia, etc.
Zhengkang Su, Zhengwei Huang, Xiaoyu Chen, Xiaoyu Chen, Xi Li   +4 more
doaj   +1 more source

Nintedanib for systemic sclerosis–associated interstitial lung disease [PDF]

, 2019
BackgroundInterstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects ...
Alves, Margarida, Azuma, Arata, Clerisme-Beaty, Emmanuelle, Distler, Oliver, Fischer, Aryeh, Gahlemann, Martina, Girard, Mannaig, Highland, Kristin B., Kuwana, Masataka, Maher, Toby M., Mayes, Maureen D., Raghu, Ganesh, Sauter, Wiebke, SENSCIS Trial Investigator, for the, Smith, Vanessa, Stowasser, Susanne, Tetzlaff, Kay   +16 more
core   +3 more sources

OA19.06 CRTAM Acts as a Checkpoint of Immune-related Adverse Events Uncoupling Efficacy and Toxicity During Immunotherapy [PDF]

, 2023
Si-Cong Ma, Zi-Xuan Rong, Jr‐Rung Lin, Dafei Han, X.-T. Cai, Zhong‐Yi Dong   +5 more
openalex   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database

Scientific Reports
Fulvestrant, as the first selective estrogen receptor degrader, is widely used in the endocrine treatment of breast cancer. However, in the real world, there is a lack of relevant reports on adverse reaction data mining for fulvestrant.
Guisen Yin, Guiling Song, Shuyi Xue, Fen Liu   +3 more
doaj   +1 more source

Signalling paediatric side effects using an ensemble of simple study designs [PDF]

, 2014
Background: Children are frequently prescribed medication `o-label', meaning there has not been sucient testing of the medication to determine its safety or eectiveness.
Aickelin, U., Aickelin, U., Garibaldi, J.M., Garibaldi, J.M., Gibson, J.E., Gibson, J.E., Hubbard, R.B., Hubbard, R.B., Reps, J.M., Reps, J.M., Soria, D., Soria, D.   +11 more
core   +6 more sources

440P Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic [PDF]

, 2023
T. Pornwisetsirikul, J. Khanthawong, Jukapun Yoodee   +2 more
openalex   +1 more source

A curated and standardized adverse drug event resource to accelerate drug safety research

Scientific Data, 2016
Identification of adverse drug reactions (ADRs) during the post-marketing phase is one of the most important goals of drug safety surveillance. Spontaneous reporting systems (SRS) data, which are the mainstay of traditional drug safety surveillance, are ...
J. Banda, L. Evans, Rami Vanguri, N. Tatonetti, P. Ryan, N. Shah   +5 more
semanticscholar   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Minor Adverse Events Postcolonoscopy [PDF]

Canadian Journal of Gastroenterology and Hepatology, 2014
In recent years, the Canadian Journal of Gastroenterology and Hepatology has provided its readership with multiple publications to further our understanding of what constitutes a high-quality procedure as well as a desirable colonoscopy experience (1–4).
openaire   +3 more sources